Design
A randomized, double-blind, sham-controlled within-subjects trial design
was employed, in which participants received different tDCS protocols
(sham tDCS, 1.5mA tDCS, and 3.0mA tDCS). A two-week interval was
incorporated between the experimental sessions to mitigate any carryover
effects. The research is in line with the Declaration of Helsinki, and
it received the approval of the Ethics Committee of the Ghent University
Hospital (UZ Ghent - B6702021000839). The study was conducted at the
Ghent University Hospital of Ghent University, from March 2022 to March
2023. The current study is part of a larger project
(Razza, De Smet, et al.,
2023).